You are here

Article info

Article menu
Immunotherapy biomarkers
Original research
Soluble CD137 as a dynamic biomarker to monitor agonist CD137 immunotherapies

Authors

  • Javier Glez-Vaz Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, SpainNavarra Institute for Health Research (IDISNA), Pamplona, Spain PubMed articlesGoogle scholar articles
  • Arantza Azpilikueta Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, SpainNavarra Institute for Health Research (IDISNA), Pamplona, Spain PubMed articlesGoogle scholar articles
  • Irene Olivera Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, SpainNavarra Institute for Health Research (IDISNA), Pamplona, Spain PubMed articlesGoogle scholar articles
  • Assunta Cirella Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, SpainNavarra Institute for Health Research (IDISNA), Pamplona, SpainDepartments of Immunology-Immunotherapy and Oncology, Clínica Universidad de Navarra, Pamplona, Spain PubMed articlesGoogle scholar articles
  • Alvaro Teijeira Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, SpainNavarra Institute for Health Research (IDISNA), Pamplona, SpainCentro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain PubMed articlesGoogle scholar articles
  • Maria C Ochoa Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, SpainNavarra Institute for Health Research (IDISNA), Pamplona, SpainDepartments of Immunology-Immunotherapy and Oncology, Clínica Universidad de Navarra, Pamplona, SpainCentro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain PubMed articlesGoogle scholar articles
  • Maite Alvarez Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, SpainNavarra Institute for Health Research (IDISNA), Pamplona, SpainDepartments of Immunology-Immunotherapy and Oncology, Clínica Universidad de Navarra, Pamplona, SpainCentro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain PubMed articlesGoogle scholar articles
  • Iñaki Eguren-Santamaria Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, SpainNavarra Institute for Health Research (IDISNA), Pamplona, Spain PubMed articlesGoogle scholar articles
  • Carlos Luri-Rey Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, SpainNavarra Institute for Health Research (IDISNA), Pamplona, Spain PubMed articlesGoogle scholar articles
  • Maria E Rodriguez-Ruiz Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, SpainNavarra Institute for Health Research (IDISNA), Pamplona, SpainDepartments of Immunology-Immunotherapy and Oncology, Clínica Universidad de Navarra, Pamplona, SpainCentro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain PubMed articlesGoogle scholar articles
  • Xinxin Nie Department of Immunobiology, Yale University School of Medicine, New Haven, Connecticut, USA PubMed articlesGoogle scholar articles
  • Lieping Chen Department of Immunobiology, Yale University School of Medicine, New Haven, Connecticut, USADepartment of Medicine (Medical Oncology), Yale University School of Medicine, New Haven, Connecticut, USA PubMed articlesGoogle scholar articles
  • Sonia Guedan Department of Hematology and Oncology, Hospital Clinic. Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain PubMed articlesGoogle scholar articles
  • Miguel F Sanmamed Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, SpainNavarra Institute for Health Research (IDISNA), Pamplona, SpainDepartments of Immunology-Immunotherapy and Oncology, Clínica Universidad de Navarra, Pamplona, SpainCentro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain PubMed articlesGoogle scholar articles
  • Jose Luis Perez Gracia Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, SpainNavarra Institute for Health Research (IDISNA), Pamplona, SpainDepartments of Immunology-Immunotherapy and Oncology, Clínica Universidad de Navarra, Pamplona, SpainCentro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain PubMed articlesGoogle scholar articles
  • Ignacio Melero Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, SpainNavarra Institute for Health Research (IDISNA), Pamplona, SpainDepartments of Immunology-Immunotherapy and Oncology, Clínica Universidad de Navarra, Pamplona, SpainCentro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain PubMed articlesGoogle scholar articles

Citation

Glez-Vaz J, Azpilikueta A, Olivera I, et al
Soluble CD137 as a dynamic biomarker to monitor agonist CD137 immunotherapies
Journal for ImmunoTherapy of Cancer 2022;10:e003532. doi: 10.1136/jitc-2021-003532
Online issue publication 
October 18, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.